Letters Pioglitazone use and risk of bladder cancer

Authors’ reply to Gallagher and Winocour

BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i3668 (Published 06 July 2016) Cite this as: BMJ 2016;354:i3668
  1. Laurent Azoulay, associate professor of oncology1 2,
  2. Kristian B Filion, assistant professor of medicine1 3 4
  1. 1Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
  2. 2Department of Oncology, McGill University, Montreal
  3. 3Department of Epidemiology, Biostatistics, and Occupational Health, McGill University
  4. 4Division of Clinical Epidemiology, McGill University
  1. laurent.azoulay{at}mcgill.ca

We thank Gallagher and Winocour for their interest in our work.1 Pioglitazone trials were not designed to assess safety endpoints such as bladder cancer. Consequently, the presence of an imbalance between the randomised groups necessitates further inquiry. While we agree that some early events in the PROactive trial are unlikely to be causally …

View Full Text

Sign in

Log in through your institution

Subscribe